Edition:
United Kingdom

Pharming Group NV (PHAR.AS)

PHAR.AS on Amsterdam Stock Exchange

1.30EUR
23 Feb 2018
Change (% chg)

€-0.06 (-4.49%)
Prev Close
€1.36
Open
€1.38
Day's High
€1.39
Day's Low
€1.29
Volume
27,683,068
Avg. Vol
31,481,199
52-wk High
€1.62
52-wk Low
€0.28

Select another date:

Wed, Jan 17 2018

BRIEF-Pharming Announces FDA Acceptance For Review Of Supplemental Biologics License Application

* PHARMING ANNOUNCES FDA ACCEPTANCE FOR REVIEW OF SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR RUCONEST® FOR PROPHYLAXIS OF HEREDITARY ANGIOEDEMA ATTACKS

BRIEF-Pharming Group Announces Further Conversion Of Ordinary Convertible Bonds

* BONDHOLDERS CONVERT €7.7 MILLION OF THEIR REMAINING BONDS INTO PHARMING SHARES AND CASH

BRIEF-Pharming Group Announces Significant Conversion Of Its Ordinary Convertible Bonds

* PHARMING ANNOUNCES SIGNIFICANT CONVERSION OF ITS ORDINARY CONVERTIBLE BONDS

BRIEF-Pharming Submits License Application to FDA for Ruconest

* PHARMING SUBMITS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION TO FDA FOR RUCONEST® FOR PROPHYLAXIS OF HEREDITARY ANGIOEDEMA ATTACKS

BRIEF-Pharming Group Q3 net result swings to profit of 7.5 million euros from Q2

* ‍Q3 NET RESULT IMPROVED TO EUR 7.5 MILLION LOSS COMPARED WITH A LOSS OF EUR 24.5 MILLION IN Q2​

BRIEF-Pharming Group announces positive data from paediatric clinical trial of Ruconest

* PHARMING ANNOUNCES POSITIVE DATA FROM PAEDIATRIC CLINICAL TRIAL WITH RUCONEST®

BRIEF-Pharming Group partners with Inceptua Medicines Access

* PHARMING GROUP N.V. AND HAEI INTERNATIONAL PATIENT ORGANIZATION ANNOUNCE PARTNERSHIP WITH INCEPTUA MEDICINES ACCESS FOR "HAEI GLOBAL ACCESS PROGRAM"

BRIEF-Pharming announces conclusion of FDA end of phase 2 interactions on Ruconest

* PHARMING ANNOUNCES CONCLUSION OF FDA END OF PHASE 2 INTERACTIONS ON RUCONEST FOR PROPHYLAXIS OF HAE

Select another date: